Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
AVALON PHARMACEUTICALS INC (AVRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/13/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Second Quarter 2008 Results Company also announces that it is restructuring operations Germantown, Md., August 13, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the second quarter of 2008. For the three months ended June 30, 2008, net loss was $5.6 million, compared with $5.8 million in the second quarter of 2007. As of June 30, 2008, cash, cash equivalents and marketable securities totaled $16.7 million. The Company also announced today that it is restructuring its operations and reducing its workforce by approximately one-third. “In the second quarter of 2008, we reached an important milestone for Av..." |
|
| 05/07/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports First Quarter 2008 Results Germantown, Md., May 7, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the first quarter of 2008. For the three months ended March 31, 2008, net loss was $6.2 million, compared with $5.3 million in the first quarter of 2007. As of March 31, 2008, cash, cash equivalents and marketable securities totaled $23.6 million. “Our clinical trials, pre-clinical product development programs and major collaborations continued to progress as planned in the first quarter of 2008,” stated Kenneth C. Carter, Ph.D., President and CEO. “We are excited about recent progress in our Aurora/Centros..." |
|
| 03/19/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results Germantown, MD, March 19, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the fourth quarter and full year of 2007. For the three months ended December 31, 2007, net loss was $5.1 million, compared with $4.4 million in the fourth quarter of 2006. For the year ended December 31, 2007, net loss was $21.7 million, compared with a loss of $17.1 million for 2006. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $28.5 million. “Avalon continues to execute on our corporate strategy of building a pipeline of first-in-class drugs for Avalo..." |
|
| 11/07/2007 |
8-K
| Quarterly results |
| 08/08/2007 |
8-K
| Quarterly results |
| 05/10/2007 |
8-K
| Quarterly results |
| 03/21/2007 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Results Germantown, Md., March 21, 2007 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company using its proprietary technology, AvalonRx®, to discover and develop cancer therapeutics, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2006. For the three months ended December 31, 2006, total revenues were $0.7 million and net loss was $4.4 million. For the fiscal year ended December 31, 2006, total revenues were $2.7 million and net loss was $17.1 million. As of December 31, 2006, cash, cash equivalents and marketable securities totaled $20.4 million. This amount does not include the $9.5 million of net proceeds from the equity offering completed..." |
|
| 11/07/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Third Quarter 2006 Results GERMANTOWN, MD, November 7, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the third quarter and nine months ended September 30, 2006. “In the third quarter of 2006, our internal discovery and development programs focused on novel drugs to treat cancer continued to make great progress and we continue to be encouraged by the progress of our phase I clinical trial for AVN944, showing tolerance by patients to increasing dose levels,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “Our discovery programs and partnerships with Novartis, MedImmune and ChemDiv also continue to adva..." |
|
| 08/08/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Second Quarter 2006 Results GERMANTOWN, MD, August 8, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the second quarter and six months ended June 30, 2006. “As we progress with AVN944 and our drug discovery programs, the recently announced addition of a Chief Medical Officer will help guide clinical development and regulatory strategies,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “We are also very pleased with the progress of our current partnerships and the formation of a new partnership with ChemDiv, Inc. Through these partnerships, which expand the use of our proprietary technology, AvalonRx®,..." |
|
| 05/10/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports First Quarter 2006 Results GERMANTOWN, MD, May 10, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the quarter ended March 31, 2006. “During the first quarter of 2006, we made excellent progress on our internal product development programs, which are focused on new treatments for cancer, the discovery of biomarkers to guide development of our lead drug AVN944, and on our partnerships, which expand the use of our proprietary technology, AvalonRx®, into other disease areas,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “During the remainder of 2006, we look forward to continued progress on these progra..." |
|
| 03/07/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Results GERMANTOWN, MD, March 7, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the quarter and twelve months ended December 31, 2005. “2005 was a pivotal year for Avalon and we believe it will be the springboard for our growth in future years,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “We became a clinical stage oncology company by advancing AVN944 into a Phase I trial, made significant progress in drug discovery with two of our internal drug discovery programs moving into lead optimization and established two new discovery partnerships. In addition, we improve..." |
|
| 11/08/2005 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Third Quarter 2005 Results GERMANTOWN, MD, November 8, 2005 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the quarter and nine months ended September 30, 2005. “In the first nine months of 2005, Avalon has made significant progress delivering on our corporate objectives,” stated Kenneth C. Carter, Ph.D., President and CEO. “We have acquired a clinical phase oncology compound, established two drug discovery partnerships, filed and activated our first IND, and completed our IPO. Looking ahead, the initiation of clinical trials in cancer patients with AVN944, further progress on our beta-catenin and aurora kinase inhibitor..." |
|
|
|